Novel Platform For Treatment Of Breast And Pancreatic Cancer Developed

Scientists have identified a novel synthetic compound that sharply inhibits the activity of a protein that plays an important role in in the progression of breast and pancreatic cancers. In the new study, to be published in the journal Molecular Pharmacology, the scientists showed that the compound, known as SR1848, reduces the activity and expression of the cancer-related protein called "liver receptor homolog-1" or LRH-1.
 
LRH1 plays a crucial role in breast cancer through its regulation of genes involved in hormone synthesis and cholesterol metabolism - also key risk factors in cardiovascular disease. LRH-1 has also been implicated as a tumor promoter in intestinal and pancreatic cancer. Overexpression of LRH-1 has been shown to promote invasiveness and metastasis, the usually lethal spread of the disease. This suggests that repressing LRH-1 could be useful in treating the more aggressive triple-negative breast cancer subtype where therapies are currently so limited.
 
In fact, the study showed that levels of LHR-1 in a cell's nucleus began to diminish four hours after treatment with SR1848, and the compound repressed specific target genes as early as two hours after administration.
 
The researchers noted that SR1848 also appears attractive as a potential therapeutic because of its lack of impact on cells that do not express LRH1, which could mean few potential side effects.
 
Originally posted by Scripps Research Institute.